TipRanks
Go Ultimate55% OFF

Satellos Bioscience (MSCL) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Sat-3247Muscular Dystrophies, Duchenne Muscular Dystrophy, Neuromuscular Diseases, Dmd, DuchennePhase IIActive Not RecruitingPhase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsDec 11, 2025―
Sat-3247Duchenne Muscular Dystrophy (Dmd)Phase IIEnrolling By InvitationA Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 StudyMar 04, 2025
Sat-3247Duchenne Muscular DystrophyearlyPhase1CompletedFirst in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK CohortAug 19, 2024―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Satellos Bioscience Inc. (TSE:MSCL) have in its pipeline
Satellos Bioscience TSE:MSCL is currently developing the following drugs: Sat-3247. These drug candidates are in various stages of clinical development as the company works toward FDA approval.